Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Late-onset Neonatal Sepsis (suPAR)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01294865|
Recruitment Status : Unknown
Verified December 2009 by Ankara University.
Recruitment status was: Active, not recruiting
First Posted : February 14, 2011
Last Update Posted : February 14, 2011
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||120 participants|
|Observational Model:||Case Control|
|Official Title:||The Plasma Levels of suPAR in Late-onset Neonatal Sepsis|
|Study Start Date :||January 2010|
|Estimated Primary Completion Date :||January 2012|
|Estimated Study Completion Date :||June 2012|
Infants having clinical suspected late-onset neonatal sepsis enrolled in the study. Blood samples for suPAR were obtained before initiating antibiotic treatment and at the end of the treatment with other laboratory tests.
Infants without any clinical or hematological septic signs. Blood samples will be taken only once.
- Levels of suPAR in late-onset neonatal sepsis [ Time Frame: three weeks ]Levels of suPAR will be dosed with suspicion of late-onset sepsis diagnosis at day 0 and at the end of the treatment. The evolution and the best cut-off values will be calculated for the diagnosis. Indices of sensibility, specificity, positive predictive value and negative predictive value will be calculated.
- Level of plasma C-reactive protein [ Time Frame: three weeks ]Plasma C-reactive protein levels to confirm the diagnostic usefulness of suPAR measurements at diagnosis and end of the treatment
- the white blood cell count [ Time Frame: three weeks ]the white blood cell counts to confirm the diagnostic usefulness of suPAR measurements at diagnosis and end of the treatment
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01294865
|Ankara University Faculty of Medicine, Department of Pediatrics|
|Ankara, Turkey, 06620|
|Study Director:||Saadet Arsan, Professor||Ankara University|